The Medical Journal of Australia ISSN: 0025-729X 16 January 2012 196 1 58-61 ©The Medical Journal of Australia 2012 www.mja.com.au Research oncerns are increasing in Australia and internationally that the supply of medical oncologists (MOs) is insufficient to meet the rising demand. [1] [2] [3] [4] [5] The only study of the medical and haematological oncology workforce in Australia was published in 2001. 6 This study found that there were 180 MOs in active practice in Australia (0.9 per 100 000 population), and an estimated shortfall of at least 40 medical and haematological oncologists.
The best estimate of the number of MOs in Australia in 2009 was 311, based on the membership of the Medical Oncology Group of Australia (MOGA), the peak representative body for MOs in Australia. This equates to 1.4 MOs per 100 000 population. Despite the increase since 2001, this figure is still well below comparable international figures, such as the 3.5 MOs per 100 000 population reported in the United States in 2005. 7 In response to consumer concerns about the medical oncology workforce shortage, the Australian Medical Oncologist Workforce Study was initiated by MOGA in 2009. The purpose of this cross-sectional study was to evaluate the current and future capacity of the MO workforce by estimating the supply, demand and shortfall of MOs in Australia in 2009 and 2014.
Methods

Study population
Lead clinicians, directors, or solo practitioners ("lead clinicians") of all public and private adult medical oncology practices in Australia were invited to complete a self-administered survey. Lead clinicians could represent more than one practice. Practices and lead clinicians were identified using the MOGA membership database, consumer directories and databases of state and federal departments of health. Institutional human research ethics committee approval of the study was obtained from the University of Wollongong. The number of FTE MOs describes the number of full-time equivalent staff members each working 40 hours per week. We distinguished chemotherapy agents from other anticancer agents according to the SEER*Rx Interactive Antineoplastic Drug Database. 8 "Rural" included all non-metropolitan locations by the rural, remote and metropolitan areas classification. 9 The survey was developed with the MOGA workforce study working group, following a comprehensive literature review, and could be completed on paper or as an online questionnaire. The survey was administered in July and August 2009. Lead clinicians were initially sent a letter of invitation to participate by post and by email, a participant information sheet, the paper survey, a hyperlink to the online survey and one reminder by email. Non-responding lead clinicians were contacted by telephone and sent two reminders by email as required. 10 The projected number of new cases of cancer in Australia during 2014 assumed a growth of 2% per year. 10 The populations of each state and territory in June 2009 were obtained from the Australian Bureau of Statistics. 11 An optimal chemotherapy utilisation rate of 51% was based 
Statistical analysis
Descriptive statistics were used to summarise the responses to the survey at state, territory and national levels. Calculations excluded practices that reported missing data for the relevant item. The chemotherapy utilisation rate was calculated as the ratio of the number of new patients reported in the survey to be receiving chemotherapy, and the new cases of cancer reported to state and territory cancer registries.
The 
Discussion
We identified a current shortage of MOs in Australia, expected to persist in the future. A conservative estimate of the current supply, demand and shortfall of MOs was 234, 326 and 92 FTE respectively (at a workload of 150 new patients/FTE MO/year). Shortfalls of MOs were found in all states and territories and in metropolitan and rural centres.
MOs in Australia in 2008 had a high clinical workload compared with international benchmarks. The average number of new patients per FTE MO of 270 is well above Canadian recommendations of 160 to 175 1 and the suggested Australian benchmark of 150 new patients per year. 13 Reduction of this clinical workload requires training more than double the estimated shortage of FTE MOs, given that the average FTE per MO was 0.5 (Box 2). The increasing diversification of MOs into non-clinical roles will only increase the demand on clinical responsibilities should the shortage not be addressed.
The national chemotherapy utilisation rate was surprisingly low, and well below the evidence-based Australian standard of 51%. 12 This is of concern because it implies that some patients who may benefit from chemotherapy are not receiving it. Possible explanations for a low chemotherapy utilisation rate include suboptimal referral rates of patients with cancer, patients referred with advanced rather than early stage cancer, and low prescribing rates of chemotherapy to new patients with cancer. We suspect that we have underestimated the chemotherapy utilisation rate, because only one-third of centres (representing about 60% of the total national MO workload) reported the number of new patients who received chemotherapy. However, even correcting for the underestimate, it is unlikely that chemotherapy utilisation in Australia approximates expected standards.
The number of trainees was greater than the number MOs expected to retire. This suggests that the supply of MOs should be able to meet the increased demand over the next 5 years, assuming full integration of the trainees into the medical oncology workforce. However, allowing for part-time work practices, overseas Although not directly comparable, our findings are similar to the results of the most recent study of the oncology workforce in the US, 7 and studies of the medical workforce in other oncology specialties such as radiation oncology 14 and palliative care. 15 The US study found that demand for MOs is expected to rise by 48% between 2005 and 2020, but supply will only rise 14%, translating into a shortfall of 2550 to 4080 oncologists (about one-quarter to one-third of the 2005 supply).
Our study has several limitations. The response rate of 81% was acceptable, but may not have been high enough to generalise the results to all MOs and practices in Australia. Lead clinicians, rather than individual MOs, were surveyed to maximise the response rate, but this was at the cost of detailed knowledge about workplace patterns of individual MOs. Only the clinical workload of MOs rela ting t o chem otherapy was included, so the results may have underestimated the true workload of MOs in Australia, which also includes other systemic therapies such as hormonal therapy. Our study highlighted the lack of basic data collection at some oncology practices. Some responses were estimated rather than counted, and many centres were unable to provide any data about workload. This reduced the accuracy of the results and is likely to have underestimated the workload relating to new patients.
Despite these limitations, we provide a snapshot of the current medical oncology workforce in Australia, and an estimate of the current and future workforce shortages. Addressing the shortage needs a multilevel approach aimed at increasing the supply of MOs by increasing recruitment, training and participation rates, improving clinical practice efficiency, and the introduction of innovative methods of service delivery through involvement of other health professionals and use of models of shared care.
Tailored national strategies will be necessary to ensure an adequate medical oncology workforce in the future, and ongoing monitoring will be needed to guide and promote the strategies.
